Brexpiprazole: A New Treatment Option for Schizophrenia.
Schizophrenia occurs in approximately 0.3 to 0.7 percent of the world's population and is associated with significant morbidity and mortality. Although atypical antipsychotics reduce positive and negative symptoms, they are associated with varying degrees of metabolic adverse effects. This necessitates continued development of efficacious yet metabolically favorable treatments. This article reviews brexpiprazole, a medication recently approved to treat patients with schizophrenia. Brexpiprazole was well-tolerated, and adverse reactions were statistically insignificant. They included nausea; insomnia; headache; agitation; akathisia; and weight gain or changes in lipid, creatine phosphokinase, glucose, or prolactin levels. Brexpiprazole is taken once daily without regard to food, and the dose should be adjusted in patients who receive moderate or strong CYP450 inhibitors or inducers and in patients with hepatic or renal disease.
Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina.
Jonathan R
JR
Scarff
Schizophrenia; antipsychotic; brexpiprazole
Epidemiol Rev. 2008;30:67-76
18480098
Schizophr Res. 2015 May;164(1-3):127-35
25682550
J Clin Psychiatry. 2007;68 Suppl 4:4-7
17539693
Int J Clin Pract. 2015 Sep;69(9):978-97
26250067
J Pharmacol Exp Ther. 2014 Sep;350(3):589-604
24947465
Int Clin Psychopharmacol. 2016 Jul;31(4):192-201
26963842
Int J Neuropsychopharmacol. 2017 Jan 1;20(1):11-21
27566723
Eur Neuropsychopharmacol. 2015 Mar;25(3):356-64
25600995
Am J Psychiatry. 2015 Sep 1;172(9):870-80
25882325
Br Med Bull. 2015 Jun;114(1):169-79
25957394
Acta Psychiatr Scand. 2000 Apr;101(4):323-9
10782554
J Pharmacol Exp Ther. 2014 Dec;351(3):585-95
25225185
J Pharmacol Exp Ther. 2014 Sep;350(3):605-14
24947464